Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Heart health under the microscope: landmark study on Gender-Affirming hormones launches

NCT ID NCT07128771

First seen Jan 11, 2026 · Last updated Jun 07, 2026 · Updated 22 times

Summary

This study follows 450 people with gender incongruence who are starting or continuing gender-affirming hormone therapy. Researchers will use heart scans, blood tests, and quality-of-life surveys over time to see if the therapy has negative, neutral, or positive effects on the heart. The goal is to provide clear information to help patients and doctors make informed decisions together.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR DISEASE (CVD) RISK FACTORS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Oslo University Hospital

    Oslo, Oslo, Norway

Conditions

The condition(s) this trial relates to.

cardiovascular disorder Gender Dysphoria heart disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.